Name
Purdue University Globle
NU553 Advanced Pharmacology and Pharmacotherapeutics
Prof. Name
Date
Understanding neurotransmitters, medication mechanisms, adverse effects, and patient monitoring is essential for advanced psychiatric and pain management practice. This study guide explains the most important pharmacology concepts for U553 Unit 2, including antidepressants, anxiolytics, antipsychotics, mood stabilizers, ADHD medications, sleep therapies, and pain management. The key to safe prescribing is matching treatment to the patient’s condition, monitoring therapeutic response and toxicity, and combining medication with appropriate behavioral and non-pharmacologic interventions.
The guide below is designed to support nursing and nurse practitioner students with high-yield medication facts, clinical decision-making principles, and practical exam review. Medication choices, doses, and monitoring requirements must always be verified against current prescribing information and clinical guidelines.
Neurotransmitters are chemical messengers that allow neurons to communicate throughout the brain and nervous system. They influence mood, cognition, anxiety, attention, sleep, movement, and behavior. Understanding neurotransmitter function helps advanced practice providers connect psychiatric symptoms with medication mechanisms.
Although neurotransmitter theories are useful for understanding pharmacology, psychiatric disorders are not caused by a single neurotransmitter imbalance. Depression, anxiety, bipolar disorder, and schizophrenia involve complex interactions among neurotransmitters, neural circuits, genetics, and environmental factors.
Clinical prescribing requires more than identifying a neurotransmitter. Providers must consider the patient’s symptoms, diagnosis, previous treatment response, medical history, and potential adverse effects.
Important treatment considerations include:
Medication effectiveness and evidence-based indications.
Adverse effects, drug interactions, and contraindications.
Patient preferences and treatment goals.
Medical and psychiatric comorbidities.
Medication adherence and affordability.
Safety monitoring and long-term follow-up.
Pharmacotherapy is often most effective when combined with psychotherapy, lifestyle modification, patient education, and appropriate social support.
These associations help explain why clinicians use antidepressants, anxiolytics, antipsychotics, stimulants, and sleep medications. However, treatment should be guided by the diagnosed condition and clinical evidence rather than by a presumed neurotransmitter deficiency alone.
Antidepressants are used to treat major depressive disorder and several anxiety disorders. Some are also prescribed for neuropathic pain, obsessive-compulsive disorder, panic disorder, and other conditions.
Selective serotonin reuptake inhibitors (SSRIs) are commonly recommended as first-line pharmacologic options for major depressive disorder and many anxiety disorders. They are generally well tolerated and have a more favorable safety profile than older antidepressants.
Common SSRIs include:
Sertraline (Zoloft)
Fluoxetine (Prozac)
Citalopram (Celexa)
Escitalopram (Lexapro)
Serotonin-norepinephrine reuptake inhibitors (SNRIs) increase serotonin and norepinephrine signaling. Examples include venlafaxine and duloxetine. Duloxetine is also used for certain chronic pain conditions, including diabetic peripheral neuropathic pain and fibromyalgia.
Medication selection should be individualized according to:
Presenting symptoms and psychiatric diagnosis.
Previous medication response.
Medical comorbidities.
Drug interactions.
Adverse-effect concerns.
Patient preferences and treatment goals.
Bupropion is an activating antidepressant that affects norepinephrine and dopamine signaling. It may be useful when low energy or reduced motivation is prominent. It is also commonly considered when sexual dysfunction associated with serotonergic antidepressants is a concern. It should be avoided in patients with a seizure disorder or current or prior anorexia nervosa or bulimia nervosa because of increased seizure risk.
Mirtazapine is an antidepressant that commonly causes sedation and increased appetite. It may be useful for patients with depression who also experience insomnia or reduced appetite. Sedation and weight gain should be discussed during treatment planning.
Antidepressant treatment requires follow-up to assess symptom improvement, adherence, tolerability, and safety. Clinical improvement may take several weeks, and treatment response varies among patients.
Important monitoring considerations include:
Worsening depression or emerging suicidal thoughts.
Increased agitation, restlessness, or unusual behavioral changes.
Serotonin syndrome when serotonergic medications are combined.
Sexual dysfunction, gastrointestinal symptoms, or sleep changes.
Medication adherence and treatment response.
Symptoms of mania or hypomania in patients with possible bipolar disorder.
Suicide risk monitoring is especially important in adolescents and young adults beginning antidepressant therapy or experiencing dose changes. Increased energy before mood improvement may create a clinical concern, but the relationship between antidepressants, energy, and suicide risk is complex and should not be assumed in every patient.
Antidepressants should generally be tapered gradually when discontinuing treatment, unless an urgent clinical situation requires otherwise. Abrupt discontinuation can cause withdrawal or discontinuation symptoms, particularly with medications such as paroxetine and venlafaxine.
Anxiolytics are medications used to reduce anxiety symptoms. The appropriate choice depends on the type of anxiety disorder, symptom severity, duration, comorbidities, and risk of medication misuse.
Benzodiazepines enhance the effects of gamma-aminobutyric acid (GABA) at GABA-A receptors. They produce rapid anxiolytic effects and may be prescribed for selected acute or short-term situations.
Examples include alprazolam, lorazepam, and clonazepam.
Because of their potential for dependence, misuse, withdrawal, sedation, and respiratory depression, benzodiazepines are generally not preferred as long-term treatment for chronic anxiety disorders.
Important safety considerations include:
Tolerance and physical dependence.
Sedation, impaired coordination, and falls.
Increased respiratory depression when combined with opioids or other CNS depressants.
Avoiding alcohol and other sedating substances.
Gradual tapering when discontinuing long-term therapy.
Increased risk of adverse effects in older adults.
Buspirone is a non-benzodiazepine anxiolytic commonly used for generalized anxiety disorder. It acts primarily through serotonin 5-HT1A receptor activity.
Important characteristics include:
Lower abuse potential than benzodiazepines.
Usually less sedating than benzodiazepines.
Not intended for immediate relief of acute panic symptoms.
Requires regular administration and time for therapeutic benefit.
Buspirone is not an appropriate substitute for emergency treatment of severe acute anxiety, psychosis, or an imminent safety crisis.
SSRIs and SNRIs are commonly recommended for long-term pharmacologic treatment of generalized anxiety disorder, panic disorder, and other anxiety conditions. Cognitive behavioral therapy (CBT) is also an important evidence-based treatment.
Other helpful interventions include relaxation techniques, sleep improvement, physical activity, and patient education. Treatment should be individualized to the patient’s diagnosis and preferences.
Antipsychotic medications are used to treat schizophrenia and other psychotic disorders. Some are also prescribed for bipolar disorder, severe mood episodes, and selected treatment-resistant depression indications.
First-generation or typical antipsychotics primarily block dopamine D2 receptors. They are effective for many positive symptoms of schizophrenia, such as hallucinations and delusions.
Examples include haloperidol, chlorpromazine, and fluphenazine.
A major concern is the risk of extrapyramidal symptoms (EPS), including:
Acute dystonia.
Akathisia.
Drug-induced parkinsonism.
Tardive dyskinesia.
Tardive dyskinesia may involve repetitive, involuntary movements of the tongue, face, jaw, fingers, or limbs. Regular assessment using a structured tool such as the Abnormal Involuntary Movement Scale (AIMS) may be appropriate.
Second-generation or atypical antipsychotics affect dopamine and serotonin receptors. Many have a lower risk of certain movement disorders than high-potency first-generation agents, although EPS and tardive dyskinesia can still occur.
Examples include:
Risperidone.
Olanzapine.
Quetiapine.
Aripiprazole.
Ziprasidone.
Clozapine.
These medications differ significantly in their metabolic, neurologic, cardiovascular, and sedating effects. The choice should be based on the patient’s condition and the medication’s risk profile.
Antipsychotic therapy requires baseline and follow-up assessment. Monitoring should include:
Weight and body mass index (BMI).
Waist circumference when appropriate.
Blood pressure.
Fasting glucose or hemoglobin A1c.
Lipid profile.
Extrapyramidal symptoms and tardive dyskinesia.
Sedation and orthostatic hypotension.
Medication adherence and symptom response.
A comprehensive metabolic panel may be ordered when clinically indicated, but metabolic monitoring should not be limited to a CMP.
Clozapine is an important treatment option for treatment-resistant schizophrenia and for reducing recurrent suicidal behavior in selected patients with schizophrenia or schizoaffective disorder.
It carries a risk of severe neutropenia, myocarditis, seizures, constipation, and metabolic complications. Monitoring requirements depend on current regulatory guidance and local protocols.
Clinicians should assess:
Absolute neutrophil count (ANC) and required blood monitoring.
Infection symptoms.
Constipation and gastrointestinal complications.
Myocarditis symptoms.
Seizure risk.
Metabolic adverse effects.
Neuroleptic malignant syndrome (NMS) is a rare, potentially fatal reaction associated with dopamine-blocking medications. It is a medical emergency.
Classic findings include:
High fever.
Severe muscle rigidity.
Altered mental status.
Autonomic instability, such as tachycardia and blood pressure changes.
Elevated creatine kinase and possible rhabdomyolysis.
Risk factors may include high-potency antipsychotics, rapid dose escalation, dehydration, and previous NMS. Suspected NMS requires immediate medical evaluation, stopping the suspected medication under clinical supervision, and supportive emergency treatment.
Mood stabilizers are used primarily in bipolar disorder to reduce manic symptoms, prevent mood episodes, and support long-term maintenance. Different medications have different indications and monitoring requirements.
Lithium is a well-established treatment for bipolar disorder. It is used for acute mania and maintenance treatment, and it has evidence supporting reduction in suicide risk in appropriate patients.
Lithium has a narrow therapeutic index, making regular monitoring essential. The appropriate serum concentration depends on the treatment phase, clinical response, age, kidney function, and other factors. Common maintenance targets are often around 0.6–1.0 mEq/L, while some patients require higher concentrations during acute treatment.
Lithium monitoring includes:
Serum lithium concentration.
Kidney function and electrolytes.
Thyroid function.
Hydration status.
Medication interactions.
Clinical signs of toxicity.
Patient education should emphasize consistent fluid intake, avoiding major changes in dietary sodium without medical guidance, and reporting illness that causes dehydration.
NSAIDs, ACE inhibitors, ARBs, and certain diuretics may increase lithium concentrations. Patients should consult their prescriber before starting or stopping these medications.
Signs of lithium toxicity may include:
Worsening tremor.
Nausea, vomiting, or diarrhea.
Ataxia or unsteady gait.
Confusion.
Slurred speech.
Severe weakness.
Suspected lithium toxicity requires urgent medical evaluation.
Lamotrigine is particularly important for maintenance and prevention of depressive episodes, but it is not a treatment for acute mania. Patients must be educated about rash and serious skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.
Valproate carries significant fetal risk and should generally be avoided in pregnancy when effective alternatives are available, particularly for bipolar disorder and migraine prevention. Pregnancy planning requires individualized counseling and specialist involvement.
Attention-deficit/hyperactivity disorder (ADHD) is associated with differences in attention and executive-function networks involving dopamine and norepinephrine signaling. Medication improves symptoms such as inattention, impulsivity, and hyperactivity in many patients.
Stimulants are commonly considered first-line pharmacologic treatment for ADHD.
Examples include:
Methylphenidate.
Amphetamine-based preparations.
They increase catecholamine signaling and may improve concentration and impulse control.
Non-stimulant options include atomoxetine, guanfacine, and clonidine. They may be useful when stimulants are not tolerated, ineffective, or unsuitable for the patient’s clinical situation.
Medication selection should consider cardiovascular history, coexisting psychiatric conditions, sleep, and the risk of misuse or diversion.
Important monitoring includes:
Blood pressure and heart rate.
Appetite and weight.
Sleep quality.
Symptom improvement and functional outcomes.
Adherence and misuse risk.
Relevant personal and family cardiac history.
A cardiac history and physical assessment should be performed before starting stimulant treatment. Additional cardiac evaluation is guided by findings and clinical risk.
Sleep problems are common in psychiatric and medical conditions. Treatment begins with identifying the cause, such as insomnia, depression, anxiety, sleep apnea, medication effects, or circadian rhythm disruption.
For chronic insomnia, cognitive behavioral therapy for insomnia (CBT-I) is a preferred evidence-based treatment. Behavioral interventions may include:
Maintaining a consistent sleep schedule.
Limiting caffeine and alcohol.
Reducing exposure to stimulating activities before bedtime.
Using relaxation techniques.
Addressing poor sleep habits.
Managing underlying medical or psychiatric conditions.
Medications may be considered when clinically appropriate. Examples include zolpidem, ramelteon, low-dose doxepin, and selected other therapies.
Trazodone is frequently prescribed off-label for insomnia, although evidence for routine use is limited compared with established insomnia treatments.
Potential adverse effects include:
Next-day sedation.
Dizziness and falls.
Cognitive impairment.
Drug interactions.
Complex sleep behaviors with certain hypnotic medications.
The lowest effective dose should be used when medication is prescribed, with regular reassessment of continued need.
Medication therapy must be individualized to account for age, pregnancy status, comorbidities, and substance use history.
Older adults are more susceptible to sedation, anticholinergic effects, orthostatic hypotension, and falls. Clinicians should use the principle of “start low and go slow” while reassessing medication necessity.
Medication selection during pregnancy requires a careful risk-benefit assessment. Valproate is associated with significant fetal risks. Antidepressants and other psychotropic medications should not be stopped abruptly without medical guidance, because untreated psychiatric illness can also pose risks.
Adolescents beginning antidepressants require monitoring for worsening mood, suicidal thoughts, agitation, and unusual behavioral changes. Families should understand how and when to seek urgent help.
Patients with substance use disorders benefit from treatment plans that reduce medication-related harm. Clinicians should consider non-addictive alternatives when appropriate, use controlled-substance monitoring, and coordinate care with behavioral health and addiction specialists.
Advanced practice providers are responsible for safe, ethical, and evidence-based prescribing. Patient-centered care involves shared decision-making and clear communication about treatment benefits, risks, and alternatives.
Key responsibilities include:
Obtaining informed consent.
Reviewing medication history and allergies.
Documenting treatment decisions.
Reviewing prescription monitoring data when appropriate.
Using controlled-substance agreements when clinically indicated.
Monitoring for misuse, diversion, and adverse effects.
Collaborating with psychiatry, primary care, pain specialists, and behavioral health providers.
Protecting patient confidentiality and respecting patient autonomy.
Monitoring is an essential component of safe pharmacologic therapy. Baseline testing depends on the medication prescribed and the patient’s medical history.
Laboratory testing may include:
Complete blood count (CBC).
Electrolytes.
Renal function.
Liver function tests.
Blood glucose or hemoglobin A1c.
Lipid profile.
Pregnancy testing when clinically appropriate.
Not every patient requires every test. Monitoring should be tailored to medication-specific risks.
Validated tools can help track treatment response:
PHQ-9: Measures depressive symptoms.
GAD-7: Measures generalized anxiety symptoms.
AIMS: Assesses abnormal involuntary movements.
Other symptom scales based on the diagnosis and treatment.
Follow-up timing should reflect the medication, diagnosis, safety concerns, and clinical status. A 6- to 8-week reassessment may be useful for some antidepressant treatment decisions, but earlier follow-up is often needed for safety and tolerability.
Patients should seek urgent medical attention for severe symptoms such as suicidal thoughts with intent, high fever and rigidity, severe confusion, or suspected medication toxicity.
Effective pain management begins with identifying the type, cause, duration, and severity of pain. The goal is not only to reduce pain intensity but also to improve function, sleep, mobility, and quality of life.
Pain treatment should be individualized based on:
Pain mechanism.
Underlying diagnosis.
Severity and functional impairment.
Comorbidities.
Medication interactions.
Risk of adverse effects and dependence.
Patient preferences.
Central pain associated with CNS injury may be classified as a type of neuropathic pain. Examples include pain after stroke or spinal cord injury.
Neuropathic pain often responds better to selected adjuvant medications than to opioids alone. However, medication effectiveness varies, and treatment must be based on the diagnosis.
Pain medication should address the underlying condition whenever possible. For example, inflammatory arthritis may require disease-modifying treatment rather than relying only on analgesics.
Multimodal pain management combines medication with supportive and behavioral interventions. These approaches may reduce pain-related disability and improve long-term function.
Evidence-based and commonly used interventions include:
Heat and cold therapy.
Exercise and physical therapy.
Cognitive behavioral therapy.
Therapeutic neuroscience education.
Mindfulness and relaxation.
Massage when appropriate.
Acupuncture for selected conditions.
Transcutaneous electrical nerve stimulation (TENS) when clinically suitable.
Non-pharmacologic therapies complement appropriate medication treatment. They should not delay evaluation of potentially serious causes of pain.
Co-analgesics are medications used alongside primary pain treatments to target specific pain mechanisms or improve symptom control.
These medications are not interchangeable. Their effectiveness, adverse effects, and approved indications differ. Gabapentinoids, for example, may cause dizziness, sedation, and misuse-related concerns in some patients.
Interventional pain procedures may be considered when conservative treatment is insufficient and the pain diagnosis supports a procedure. Chronic pain is often defined as pain lasting longer than three months, although treatment decisions depend on the condition.
Examples include:
Epidural or joint injections for selected indications.
Nerve blocks.
Trigger-point injections.
Radiofrequency ablation.
Neuromodulation.
Vertebroplasty or kyphoplasty for selected vertebral compression fracture cases.
Other specialist-guided spinal procedures.
Procedures should be selected based on evidence, patient goals, potential risks, and the underlying pain generator.
Patients with opioid use disorder require compassionate, evidence-based treatment that addresses both pain and substance use. Opioid use disorder should not be treated as a reason to withhold appropriate pain care.
Clinicians should consider:
Non-opioid therapies whenever appropriate.
The lowest effective opioid dose for the shortest appropriate duration.
Multimodal pain treatment.
Functional goals rather than pain scores alone.
Prescription Drug Monitoring Program (PDMP) review.
Screening for overdose and substance use risks.
Patient education and naloxone when indicated.
Coordination with addiction medicine and other healthcare providers.
Risk assessment may include a comprehensive pain history, medication history, substance use history, and evaluation of previous treatment response. Screening tools such as the Opioid Risk Tool may support assessment but should not replace clinical judgment.
Common medications include:
Methadone: A full opioid agonist used in structured opioid treatment programs.
Buprenorphine: A partial opioid agonist used to treat opioid use disorder.
Naltrexone: An opioid antagonist used for selected patients who meet treatment requirements.
Naloxone: An opioid antagonist used to reverse opioid overdose; it is not a maintenance treatment for opioid use disorder.
Patients receiving treatment for opioid use disorder should have their current medication regimen verified before additional opioid therapy is initiated. Coordination with the treating clinician is essential.
Treatment goals include improved function, reduced overdose risk, reduced cravings, prevention of relapse, and improved quality of life.
Neurotransmitter signaling helps explain psychiatric medication mechanisms, but psychiatric disorders involve complex biological and environmental factors.
SSRIs and SNRIs are commonly used as first-line pharmacologic treatments for depression and chronic anxiety disorders.
Benzodiazepines provide rapid anxiety relief but carry dependence, sedation, and misuse risks.
Antipsychotic medications require monitoring for movement disorders, metabolic complications, and serious adverse effects.
Clozapine requires monitoring for neutropenia and other potentially severe complications.
Lithium requires regular monitoring of serum concentrations, kidney function, thyroid function, and toxicity symptoms.
ADHD medications require assessment of cardiovascular history, blood pressure, heart rate, appetite, weight, and sleep.
CBT-I and sleep hygiene are important components of insomnia management.
Chronic pain treatment should use a multimodal, mechanism-based approach.
Safe opioid prescribing requires comprehensive assessment, risk mitigation, patient education, and ongoing follow-up.
Serotonin, norepinephrine, and dopamine are commonly discussed in relation to depression. However, depression is a complex disorder involving multiple brain circuits and biological processes. SSRIs and SNRIs target serotonin and norepinephrine signaling to help reduce symptoms in many patients.
SSRIs are commonly preferred because they have demonstrated effectiveness for depression and many anxiety disorders, are generally well tolerated, and have a more favorable safety profile than older antidepressants. Treatment choice still depends on the individual patient’s diagnosis, medical history, and preferences.
Lithium treatment requires monitoring of serum lithium concentrations, kidney function, thyroid function, and electrolytes as clinically indicated. Patients should also be educated about hydration, drug interactions, and symptoms of toxicity.
Clinicians should monitor weight, BMI, blood pressure, glucose or A1c, lipid profile, movement disorders, sedation, orthostatic symptoms, adherence, and treatment response. Clozapine requires additional monitoring for neutropenia and other serious adverse effects.
SSRIs, SNRIs, and cognitive behavioral therapy are commonly recommended for chronic anxiety disorders. The choice depends on the specific diagnosis, severity, comorbidities, and patient preferences.
Chronic pain should be managed with a multimodal plan that may include exercise, physical therapy, behavioral interventions, patient education, and appropriate medications. Opioids should be considered carefully and monitored when indicated.
American Psychiatric Association. (2020). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association Publishing. https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890424841
American Psychiatric Association. (2023). The American Psychiatric Association practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association Publishing. https://psychiatryonline.org/guidelines
Centers for Disease Control and Prevention. (2022). CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. https://www.cdc.gov/overdose-prevention/hcp/clinical-guidance/
National Institute for Health and Care Excellence. (2022). Depression in adults: Treatment and management (NG222). https://www.nice.org.uk/guidance/ng222
National Institute for Health and Care Excellence. (2022). Medicines associated with dependence or withdrawal symptoms (NG215). https://www.nice.org.uk/guidance/ng215
National Institute for Health and Care Excellence. (2023). Medicines associated with dependence or withdrawal symptoms: Safe prescribing and withdrawal management. https://www.nice.org.uk/guidance/ng215
Substance Abuse and Mental Health Services Administration. (2024). TIP 63: Medications for opioid use disorder. https://store.samhsa.gov/product/tip-63-medications-opioid-use-disorder/pep24-02-011
U.S. Food and Drug Administration. (2024). Clozapine REMS program and prescribing information. https://www.fda.gov/drugs/drug-safety-and-availability/clozapine-information
U.S. Food and Drug Administration. (2024). FDA drug safety communications. https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications
